Eisai Co., Ltd. announced that the company will have a total of 34 posters, including the latest data on its in-house discovered and developed anti-seizure medication (ASM) FYCOMPA® (perampanel) CIII, at the 76th American Epilepsy Society Annual Meeting (AES 2022), to be held in Nashville, Tennessee and virtually from December 2-6, 2022. Results from a post hoc analysis of the phase III clinical trial (FREEDOM/Study 342), which evaluated long-term efficacy and safety of perampanel monotherapy by seizure type in the open-label extension (52 weeks) for epilepsy patients with newly diagnosed/currently untreated recurrent focal-onset seizures (FOS), with or without focal to bilateral tonic-clonic seizures (FBTCS), = 12 years of age from Japan and Korea (poster number: 2.228). Real-world pooled analyses of perampanel for pediatric patients (FYCOMPA® (perampanel) is indicated in patients with epilepsy aged 4 years and older for partial-onset seizures (POS) with or without secondarily generalized seizures and adjunctive therapy for patients aged 12 years and older for primary generalized tonic-clonic (PGTC) seizures.

Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients| taking FYCOMPA. FYCOMPA is a prescription medicine used in people with epilepsy aged 4 and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures, and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older. FYCOMPA, an oral medication, is a selective non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist.

The precise mechanism by which FYCOMPA exerts its antiepileptic effects in humans is unknown. In a pharmacokinetic study, it has been demonstrated that because of its long half-life, a missed dose of FYCOMPA does not significantly impact plasma levels. FYCOMPA is supplied as 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg film-coated tablets, and as a 0.5 mg/mL oral suspension formulation.

FYCOMPA has been designated by the U.S. Drug Enforcement Administration a federally-controlled substance (CIII).